Glenmark Pharmaceuticals has received marketing and manufacturing approval for antiviral drug Favipiravir on Friday.
Glenmark launches favipiravir under the brand name FabiFlu.
The chairman of Glenmark said on Saturday that he is launching a favipiravir drug.
This drug may prove to be a better drug for patients with mild to moderate COVID-19.
Glenmark is the first domestic pharma company to receive approval by DCGI,
for the use of favipiravir to the treatment of COVID-19.
Originally, this drug used in Japan for diseases such as influenza.
Many pharma companies are making this drug such as Strides, Brinton, Last Supergenerics, and Glenmark.
They also export it to many other countries where they are using this drug for COVID-19 treatment.
But many countries like Spain, Portugal, Jordan, and Turkey have been plagued by COVID-19.
And they are using this drug as a treatment for COVID-19.
As the number of people affected by the COVID-19 epidemic is increasing day by day in India. This is a piece of good news from Glenmark.
According to the company, it’s the first pharmaceutical firm in India to receive the approval for conducting phase three clinical trials on mild to moderate COVID-19 patients. “The approval comes at a time when cases in India are spiraling like never before, putting tremendous pressure on our healthcare system. We hope the availability of an effective treatment such as Favipiravir considerably help assuage this pressure,” Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd, said.News Source: Business Today
As per the company, it offers a rapid reduction in viral load in four days and provides faster symptomatic –
– and radiological improvement. The company said Favipiravir has shown clinical improvement of up to 88 percent in mild to moderate COVID-19 cases
Source: Business Today
Glenmark had also announced that it was conducting another clinical trial to evaluate the efficacy of two antivirals,News Saurce: Live Mint
Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India.
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu,
for the treatment of patients with mild to moderate COVID-19.
The Mumbai-based drug firm had on Friday received manufacturing and marketing approval from the Drugs Controller General of India (DCGI).
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19, the company said in a statement.
“This approval comes at a time when cases in India are spiraling like never before, putting tremendous pressure
on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure,
and offer patients in India a much needed and timely therapy option, he added. PTI MSS ABM ABM.
But right now we have to pray that everything will be fixed soon.